B

BioCryst Pharmaceuticals

Develops oral drugs for rare diseases

Corporate Communications Content Manager

Full-TimePosted on 9/29/2026
No salary listed
Senior
Bachelor's
Boston, MA, USA+2 moreMore locations: Durham, NC, USA | North Carolina, USA
HybridPrimarily remote, with regular in-office collaboration several days each week in Boston or Durham.

About the job

Requirements
  • A bachelor's degree in communications, journalism, marketing, or a related field is required.
  • A minimum of five years of experience in pharma, biotech, or life sciences corporate communications, in-house or agency, including familiarity with U.S. social media regulatory considerations.
  • Demonstrated success creating content across multiple channels, including executive communications, employee communications, social media, digital content, presentations, newsletters, and corporate storytelling.
  • Exceptional writing, editing, proofreading, and content development skills, including the ability to simplify complex scientific and business topics.
  • Experience managing corporate social media channels, editorial calendars, content creation, and native platform campaigns.
  • Experience designing, implementing, and analyzing paid social media campaigns.
  • Experience supporting internal communications and employee engagement initiatives.
  • A strong understanding of corporate reputation management, brand positioning, messaging, and communications best practices.
  • Experience collaborating with senior leaders, cross-functional teams, agencies, and vendors.
  • Strong organizational skills, attention to detail, and the ability to manage multiple priorities independently.
  • The ability to build relationships and influence stakeholders across all levels of the organization.
  • Availability for up to 20% domestic travel.
Responsibilities
  • Develop and produce content supporting corporate priorities, business milestones, scientific advancements, employee engagement, and corporate reputation objectives.
  • Translate complex business, scientific, and organizational information into compelling, audience-appropriate communications.
  • Create and edit communications materials, including emails, intranet content, newsletters, executive communications, presentations, event communications, social media content, and other corporate communications assets.
  • Ensure consistency of messaging, voice, tone, and brand standards across all communications channels.
  • Lead the corporate social media program, including strategy, editorial planning, content creation, publishing, community management, paid promotion, and analytics.
  • Develop and execute social media campaigns that support corporate communications objectives, thought leadership, and company milestones.
  • Monitor social media trends, conversations, risks, and opportunities to inform strategy and content development.
  • Analyze performance metrics and industry benchmarks to optimize audience engagement and content effectiveness.
  • Lead content development and publishing for internal communications channels, including email, intranet, newsletters, and events.
  • Manage internal communications intake requests, timelines, approvals, and project status.
  • Support employee engagement initiatives through strategic communications planning and content creation.
  • Support media relations activities related to company milestones, announcements, scientific developments, and strategic initiatives.
  • Monitor media coverage and develop reports, coverage summaries, and leadership updates.
  • Ensure alignment across external communications, internal messaging, and the corporate narrative.
  • Manage communications projects from concept through execution, partnering with stakeholders across the organization.
  • Coordinate with external agencies and vendors to develop communications materials and content assets.
  • Manage vendor budgets, statements of work, invoices, and related administrative processes, as appropriate.
  • Support MLR/PRC review processes, as needed.
  • Provide communications support for company meetings, employee events, leadership engagements, and other corporate activities.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience supporting media relations, media monitoring, and coverage reporting is preferred.

About the company

B

BioCryst Pharmaceuticals

View

BioCryst Pharmaceuticals develops oral small-molecule drugs aimed at treating rare diseases, with a focus on hereditary angioedema (HAE). The company uses traditional cell biology and medicinal chemistry to design synthetic compounds that target specific protein pathways involved in disease. Its products work as oral therapies that modulate disease-related proteins to reduce symptoms and improve daily functioning, progressing from discovery through clinical trials toward commercialization. BioCryst differentiates itself by concentrating on rare diseases and pursuing oral, non-biologic treatments, leveraging a combined science approach and a patient-focused strategy to bring therapies to market. Its goal is to deliver meaningful, clinically validated treatments that enable patients to engage more fully in everyday activities and improve their quality of life, supported by its drug pipeline and potential licensing opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1986

Get referred to BioCryst Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Japan approved pediatric Orladeyo on August 26, 2026, expanding revenue outside America.
  • Q2 2026 revenue hit $218.3 million, and management raised 2026 guidance to $715 million.
  • CareMed became a national Orladeyo partner on September 8, 2026, widening U.S. access.

What critics are saying

  • Pharvaris plans HAE approval in 2027, threatening Orladeyo pricing and persistence.
  • BioCryst closed Hoover in October 2026, laying off 47 and shrinking discovery capacity.
  • Orladeyo concentration remains existential; one HAE franchise funds BioCryst until navenibart proves itself.

What makes BioCryst Pharmaceuticals unique

  • Orladeyo is the only oral HAE prophylaxis approved for children aged two.
  • BioCryst now commercializes globally through specialty partners like OrphanPacific and CareMed.
  • Management quit internal discovery in 2026, focusing capital on external rare-disease asset acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 5%

1 year growth

↑ 5%

2 year growth

↑ 5%
Asianet News
Sep 9th, 2026
BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease.

BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease. Published: Sep 09 2026, 05:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. * BioCryst's Orladeyo is approved to prevent HAE attacks. * Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year. * BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst's main product. BCRX fell 9% on Tuesday and clocked its worst day since late February. A rival pill raises the bar. The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours. That market is the same one served by BioCryst's Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027. Orladeyo market. Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027. BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind. How did BCRX retail traders react? On Stocktwits, retail sentiment around BCRX rose from 'bearish' to 'neutral' over the past 24 hours, while message volume jumped from 'low' to 'high' levels. A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. "I'm really not worried... it will go up sooner than later... market trying to get rid of the weak hands," they said. View this Stocktwits post Another user opined that no one will switch out of Orladeyo even if Pharvaris's drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products. View this Stocktwits post BCRX stock has gained 16% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

The Manila Times
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. By GlobeNewswire September 9, 2026 NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) - CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact: Benito Fernandez, Chief Commercial Officer References: 1Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

BrightSpring Health Services
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. September 8, 2026 CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.[1] "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact Benito Fernandez, Chief Commercial Officer References: [1] Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

CNBC
Aug 28th, 2026
BioCryst eyes rare disease M&A as Orladeyo hits $645M in 2026 sales

BioCryst Pharmaceuticals is leveraging profits from its hereditary angioedema drug Orladeyo to acquire rare disease treatments. The company expects up to $645 million in 2026 sales from Orladeyo, which has generated over $2 billion since its 2020 FDA approval. CEO Charlie Gayer said BioCryst became profitable last year and aims to maintain profitability whilst expanding beyond being a single-product company. The firm is now seeking external acquisitions rather than internal development, targeting assets with peak sales around $300 million. This shift reflects a broader trend where small and midsize biotech companies are stepping into rare disease drug development as large pharmaceutical firms increasingly focus on multibillion-dollar assets. BioCryst's shares have risen approximately 25% since the start of the year.

Ochre Digi Media Pvt. Ltd.
Aug 26th, 2026
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients.

BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients. Wednesday, August 26, 2026 BioCryst Pharmaceuticals has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved ORLADEYO(R)(berotralstat) for the prevention of hereditary angioedema (HAE) attacks in children aged 2 to under 12 years. The once-daily oral treatment is approved as a prophylactic therapy for paediatric patients with HAE caused by C1-inhibitor deficiency. The approval provides children in Japan with an oral option for long-term prevention of HAE attacks. HAE is a rare genetic condition that can cause sudden and potentially serious swelling in different parts of the body. Traditional preventive treatment for children has often involved injections, which can add to the treatment burden for patients and caregivers. ORLADEYO is available in a granule formulation for young children. The formulation can be taken directly with water or milk, or mixed with a spoonful of soft, non-acidic food, offering a simpler method of administration. The Japanese approval is supported by interim results from the APeX-P clinical trial, which is evaluating the pharmacokinetics, safety and efficacy of ORLADEYO in children aged 2 to under 12 years with HAE due to C1-inhibitor deficiency. The study is assessing long-term prophylaxis in paediatric patients. Interim findings showed that ORLADEYO was generally well tolerated and had a consistent safety profile across the age group. The treatment also produced early and sustained reductions in monthly HAE attack rates, with no new safety concerns identified. Nasopharyngitis was the most commonly reported treatment-emergent adverse event. BioCryst plans to launch ORLADEYO for children in Japan after the completion of the country's National Health Insurance reimbursement pricing process. OrphanPacific serves as BioCryst's partner in Japan and holds the marketing authorisation for the product. ORLADEYO is a once-daily oral plasma kallikrein inhibitor designed to prevent HAE attacks. It is approved for use in more than 45 countries. The capsule formulation was first approved in Japan in January 2021 for adults and children aged 12 years and older. In December 2025, the US Food and Drug Administration approved the oral pellet formulation of ORLADEYO for the prevention of HAE attacks in children aged 2 to under 12 years. BioCryst has also submitted applications for the paediatric indication to the European Medicines Agency and Health Canada, with further regulatory submissions planned in other markets. The latest approval marks the second regulatory approval for ORLADEYO in Japan and expands access to oral preventive treatment for younger children living with HAE.